Summit Therapeutics SMMT
NASDAQ SMMT
$17.60 +0.48 (+2.77%)
As of: Sep 4, 2026 · 3:59 PM EDT

Summit Therapeutics (SMMT) EBITDA Margin Growth (3y) (2022)

Analysis

Summit Therapeutics (SMMT) EBITDA Margin Growth (3y) (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -204.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 7,045.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -1,934.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 7,261.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 9,003.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -2,649.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 30,461.00
10 Summit Therapeutics 13.67 Bn 12.98 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 -351,757.00
Mar 31, 2022 -428,427.00